MediWound Ltd. (Nasdaq: MDWD), a leading biopharmaceutical company that specializes in developing advanced biotherapeutic solutions for tissue repair and regeneration, is pleased to announce the appointment of Ms. Hani Luxenburg as its new Chief Financial Officer, effective May 14, 2023. Ms. Luxenburg will replace Mr. Boaz Gur-Lavie, who has served as MediWound’s Chief Financial Officer for the past four years. To ensure a smooth transition, Mr. Gur-Lavie will remain with the company until July 31, 2023. We are excited to have Ms. Luxenburg join our team, and we look forward to leveraging her expertise and experience as we continue to develop innovative solutions to improve patient outcomes.
Ms. Luxenburg is a highly experienced leader in financial and accounting operations, bringing over two decades of success to MediWound. She has a proven record of driving positive business growth and profitable financial results in the technology and life sciences sectors, most recently as Chief Financial Officer of BIRD Aerosystems. She also held senior finance roles at AstraZeneca, Alvarion Technologies Ltd., and Ernst & Young. Ms. Luxenburg holds a Bachelor of Law from the Interdisciplinary Center (IDC) Herzilya, Israel, a Bachelor of Arts in Economics and Accounting from the University of Haifa, Israel, and is a certified public accountant and member of the Israel Bar Association.
We are delighted to welcome Hani to the MediWound team. Her vast experience and financial expertise will be instrumental in helping us reach our goals and create lasting value for our shareholders. We are grateful to Boaz for his invaluable support in transforming MediWound, and we thank him for his financial, business development, and commercial leadership during his time with us. We wish him all the best in his future endeavours.
Ms. Luxenburg is delighted to be joining MediWound’s dynamic leadership team at such a crucial juncture. With the U.S. launch of NexoBrid imminent and the exciting EscharEx development opportunities ahead, she is eager to help the company realize its potential as a global biopharmaceutical. In her new role, she will be responsible for the day-to-day financial operations and contribute to the long-term growth of MediWound.
Working with the talented team at MediWound for the past four years has been an absolute privilege. The strategic, commercial and financial actions undertaken during this time have significantly improved the Company’s balance sheet and set it up for future growth and profitability. I’d like to thank Ofer for his leadership and for the opportunity to work with him. I’m excited to help Hani in the transition and to see MediWound continue to reach its goals.
About MediWound
MediWound is a groundbreaking biopharmaceutical company that is revolutionizing the way we approach tissue repair and regeneration. We specialize in developing and manufacturing novel, cost-effective, non-surgical bio-therapies that are designed to help repair and regenerate damaged tissue. Our cutting-edge enzymatic technology platform is focused on providing the highest quality of next-generation bioactive therapies for burn care, wound care and tissue repair.
NexoBrid® is an orphan biological product used for the early non-surgical removal of deep-partial and full-thickness thermal burns. It is a bromelain-based product that contains a sterile mixture of proteolytic enzymes and can remove burn eschar in just four hours, without harming the surrounding viable tissue. Recently approved by the FDA, NexoBrid is now available in the United States, Europe, Japan, India, and other international markets. It is supported by the US Biomedical Advanced Research and Development Authority (BARDA) and the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). NexoBrid is a revolutionary product that promises to revolutionize burn care, making early non-surgical eschar removal easier and safer.
EscharEx is making waves in the wound care industry with its promise of effective and faster debridement of chronic and hard-to-heal wounds than traditional standards of care. Results from Phase 2 trials show that EscharEx is significantly more effective and faster than SOC or placebo control when used to treat Venous Leg Ulcers and Diabetic Foot Ulcers, all while maintaining a good safety and tolerability profile. MediWound is currently in discussions with the FDA regarding the design of the pivotal Phase 3 study of EscharEx, which is expected to begin in the second half of 2023.
MW005, a topical biological drug under development, is showing promising results as a safe, well-tolerated, and effective treatment for low-risk Basal Cell Carcinoma (BCC). In a Phase I/II open-label, multicenter, randomized clinical trial conducted in the U.S., patients with BCC experienced complete clinical and histological clearance of target lesions. Study results are eagerly awaited in 2023 – with the potential to revolutionize the treatment of BCC.